Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Episodes
168 episodes
Contraline's ADAM in the clinic: towards a new era of male contraception?
When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contraceptive pill was approved by the FDA in 1960, the first IUD approved in 1968, and the female con...
•
Episode 168
•
40:33
Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play
Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people,...
•
Episode 167
•
44:49
What’s next in immunology & inflammation R&D: The trends to watch
Immunology and inflammation are hot topics in biotech and biopharma, and innovations are emerging that can change the game for patients suffering from autoimmune, gastrointestinal, and metabolic disease. For top pharma companies, identifying th...
•
Episode 166
•
51:25
BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year
Partnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, learn about new science, and put money on the table for promising biotech, it’s little wonder t...
•
Episode 165
•
44:54
AION Labs is building innovative biotechs with top pharma partners in Israel
How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these...
•
Episode 164
•
42:09
Navigating the biotech development journey from first steps to global scale with Lonza
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical...
•
Episode 163
•
50:40
A Finnish biotech is making progress on Parkinson's disease with support from The Michael J. Fox Foundation
Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnish biotech, however, is not focused on allevia...
•
Episode 162
•
38:02
How RNAi is expanding from a therapy of choice for rare disease into treating common conditions
RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions?Alnylam was the very first company to translate RNAi from Nobel Prize winning science into a commercially scalable pla...
•
Episode 161
•
48:01
Are next-generation psychedelics the way forward for addressing treatment resistant depression?
Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. One of the most common of those mental health disorders is ...
•
Episode 160
•
49:07
Day One DNA: How and why the UK is betting on whole genome sequencing for every newborn
The UK is preparing to change the game for healthcare - but why, how, and what will it cost?Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part of the country’s 10 Year Health ...
•
Episode 159
•
49:57
Meatly's innovative cultivated meat is already delighting pets, are humans next?
Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too?Traditional agricultural methods are slow, require large tracts of land, significant energy and environmental inputs, ...
•
Episode 158
•
38:45
Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience
With supply chain management and optimization, risk management, and the capacity to address global markets efficiently and effectively top of mind for all growing biotechs, I'm excited to be joined by Alison Pritchard, Vice President, Business ...
•
Episode 157
•
48:30
Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy
Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treat...
•
Episode 156
•
39:24
How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder
Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. OMass...
•
Episode 155
•
34:27
Persica Pharmaceuticals is treating the cause of chronic lower back pain, not just the symptoms
The World Health Organization reports that more than 600 million people suffer from lower back pain globally, making it the leading cause of disability worldwide. Chronic lower back pain – where the pain persists for more tha...
•
Episode 154
•
38:29
Humacyte: Saving lives with lab-grown blood vessels in conflict zones
Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte.Humacyte is pioneering a platform that...
•
Episode 153
•
36:27
Special Episode: The 2025 BIO International Convention
Much of the attention of the biotech industry has been focused on the city of Boston this week as the annual BIO International Convention hit town. BIO is the world’s largest partnering conference for the biopharma industry a...
•
Episode 152
•
38:20
Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotech
What are the most interesting questions in biotech, and is it even possible to find answers to those questions?Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, '
•
Episode 151
•
46:26
Corporate venture capital and biotechnology in 2025: challenges, opportunities, and threats
When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by firms keen to identify the next big thing in ...
•
Episode 150
•
42:12
The state of biotech finance and fundraising in Q2 2025 with Baker McKenzie
Biotechnology has always been a dynamic domain, but the world of finance that provides the fuel for the fire is just as vibrant. Trying to predict where the market for biotech investment is heading is always risky but for experts like Baker McK...
•
Episode 149
•
39:27
How generative AI and 'Photoshop for proteins' are transforming biopharma R&D
Generative artificial intelligence (GenAI) is already changing how people research, communicate, and interact, but its biggest impacts on biotech are still to come.Cradle is a Dutch-Swiss biotech startup founded in 2021 that has d...
•
Episode 148
•
35:00
Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells
There are cell therapies, gene therapies, and biologics – and then there is Immusoft. Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System Programming platform is un...
•
Episode 147
•
33:52
Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giants
Flagship Pioneering doesn't go out to find the next big thing in biotech when investing their billions in fund capital - instead, they take a different route.Flagship Pioneering has founded more than 100 companies in the life scie...
•
Episode 146
•
44:25
TCR-NK: A novel cell therapy transforming cancer treatment
Are TCR-NK treatments the next big thing in cell therapies for cancer patients?As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting signif...
•
Episode 145
•
34:00
AI in biotech today, and how it will impact the industry tomorrow
AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging?David del Bourgo is the co-founder and CEO of WhiteLab Genomics, an innovati...
•
Episode 144
•
39:40